Loading clinical trials...
Loading clinical trials...
Browse 890 clinical trials for parkinson's disease. Find studies that match your criteria and connect with research centers.
Find trials near:
Showing 601-620 of 890 trials
NCT03958708
The purposes of this clinical trial are to test 1. Whether 1-week rifaximin treatment is able to restore the gut microbiota in a long-term manner in people with Parkinson's disease? 2. Whether the restoration of gut microbiota in people with Parkinson's disease is associated with the reduction of systemic inflammation and circulating exosomal α-synuclein?
NCT02212678
The investigators are interested in evaluating the use of oral N-acetylcysteine (NAC) as therapy for Parkinson's Disease (PD) and measuring changes in brain and blood chemistry.
NCT02536976
There is a high prevalence of OAB symptoms among patients with Parkinson's disease and a lack of pharmacotherapies with an acceptable side effect profile. Specifically, available anticholinergic medications have a high risk of cognitive side-effects, which preclude their use in PD patients with CI. PD can also cause a number of non-motor symptoms that are likely to be adversely affected by the currently available anticholinergic agents. Mirabegron is the first pharmacologic treatment which may not exacerbate CI, constipation, orthostatic hypotension (OH), somnolence, and dry mouth in PD.
NCT03938974
Parkinson's disease (PD) affects 1% to 2% of the US population over age 60, and its prevalence is increasing as the population ages. The proposed research will establish the natural evolution of the social lives of people with Parkinson's disease and their families and its relationship to health outcomes, and thus has the potential to significantly advance Parkinson's disease research and evidence-based neurological nursing and rehabilitation. The project develops the new construct of social self-management of chronic disease and results will inform the development of new interventions aimed at supporting social integration and preventing isolation and loneliness in people living with Parkinson's disease.